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Abstract
Purpose Health-related quality of life (HRQOL) has not been
examined in patients with predominant antibody deficiency both
pre- and post-immunoglobulin G (IgG) treatment initiation.
HRQOL and health resource utilization (HRU) were assessed
in newly diagnosed patients with primary immunodeficiency
disease (PIDD) pre- and 12months post-IgG treatment initiation.
Methods Adults (age ≥18 years) completed the 36-item Short
FormHealth Survey, version 2; pediatric patients (PP)/caregivers
completed the Pediatric Quality of Life Inventory (PedsQL).
Scores were compared with normative data from the US gen-
eral population (GP) and patients with other chronic condi-
tions (OCC).
Results Seventeen adult patients (APs), 8 PPs, and 8 care-
givers completed baseline assessments. APs had significantly
lower baseline mean physical component summary scores
versus GP (37.4 vs 50.5, p<0.01) adults with chronic back
pain (44.1, p<0.05) or cancer (44.4, p<0.05) and lower men-
tal component summary scores versus GP (41.6 vs 49.2,
p<0.05). PPs had lower PedsQL total (63.1 vs 82.7), physical
summary (64.5 vs 84.5), and psychosocial summary (62.5 vs
81.7) scores versus GP. Post-IgG treatment, 14 APs, 6 PPs,
and 8 caregivers completed assessments. Hospital admissions
(0.2 versus 1.8, p<0.01), serious infections (3.3 versus 10.9,
p<0.01) and antibiotic prescriptions (3.0 versus 7.1; p<0.01)
decreased significantly overall. While APs reported signifi-
cant improvement in role-physical (p=0.01), general health
(p<0.01), and social functioning (p=0.02) and caregivers in
vitality (p<0.01), PPs did not.
Conclusions Pre-IgG treatment, patients with PIDD ex-
perienced diminished HRQOL versus GP and patients
with OCC; post-treatment, HRU decreased and certain
HRQOL aspects improved for APs and caregivers.
Keywords Primary immunodeficiency . antibodydeficiency .
health-related quality of life . health resource utilization, short
form health survey (SF-36) . pediatric quality of life inventory
(PedsQL)
Introduction
Primary immunodeficiency diseases (PIDDs), a heteroge-
neous group of disorders that include antibody deficiencies
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[1–4], are characterized by increased susceptibility to infec-
tions [1]. Patients with predominant antibody deficiencies can
present in infancy or adulthood [5] and are particularly vul-
nerable to bacterial infections that may result in chronic lung
disease, bronchiectasis, and gastrointestinal symptoms [2, 4,
6–8]. Affected patients experience a range of symptoms that
require lifelong treatment. Antibody replacement with immu-
noglobulin G (IgG) is the most commonly utilized
prophylactic/therapeutic approach for the management of an-
tibody deficiency disorders, and IgG administered intrave-
nously or subcutaneously has been shown to safely and effec-
tively reduce the frequency and severity of infections in these
patients [9–16].
PIDD imposes a significant disease burden on patients,
including limitations in work, play, or normal physical activity
[17, 18]. Quality of life, including health-related quality of life
(HRQOL), in patients with PIDD can be significantly affected
by delays in diagnosis [1, 19–24]. Currently, these delays are
considerable, as data from a patient survey in the United States
indicated that the average time from the onset of symptoms
associated with PIDD to the time of diagnosis is 12.4 years
[17], similar to or longer than published reports of average
delays of 12.5 years [25], 4.7 years [26], and 4.4 years [27]
from other countries. Furthermore, following treatment initia-
tion, patients have also reported lower HRQOL compared
with the general population [18, 23, 28–32]. However, details
of the HRQOL burden patients with PIDD experience both
before diagnosis and after IgG treatment initiation are lacking.
In this study we investigated the burden of disease among
patients and caregivers of pediatric patients newly diagnosed
with PIDD, focusing on patients with impaired antibody pro-
duction, and assessed the impact of IgG treatment on patient
quality of life. Our primary goal was to gain insight into the
effect of infections and impairments on HRQOL prior to and
after initiation of treatment with IgG in patients with predom-
inantly antibody deficiencies. We present comparisons of
HRQOL between patients with PIDD and age- and sex-
matched patients with other chronic conditions and the general
US population. In addition, we present an assessment of
healthcare utilization in the 6-month period preceding the start
of and 12-months following treatment initiation with IgG.
Methods
Study Design
A 12-month, prospective, uncontrolled, open-label, observa-
tional study was initiated in 2010 to assess the burden of
disease among patients with newly diagnosed predominant
antibody deficiencies and, following initiation with IgG treat-
ment, the impact of treatment on quality of life and health
resource utilization. Patients were recruited from six Jeffrey
Modell Foundation treatment centers in the United States,
Brazil, and the United Kingdom. Participating study sites of-
fered a financial incentive to study participants in the form of
(1) two $25 checks, (2) up to $50 for reimbursement of trans-
portation costs, or (3) no financial incentive, depending on the
local regulatory requirements. The appropriate institutional
review board or ethics committee at each site or country ap-
proved the study protocol.
Participants
The study focused on patients with predominant antibody de-
ficiencies in the absence of significant T-cell defects. Eligible
patients were recently diagnosed with or suspected of having
common variable immunodeficiency (CVID), XLA or auto-
somal recessive agammaglobulinemia, or specific antibody
deficiency. Diagnoses of PIDD that require treatment beyond
regular IgG replacement (eg, severe combined immunodefi-
ciency and Wiskott-Aldrich Syndrome) were excluded. All
diagnoses of PIDD were confirmed by laboratory testing and
all patients were symptomatic (ie, had recurrent infections)
and deemed suitable for IgG treatment. Both pediatric (age
<18 years) and adult (age ≥18 years) patients who qualified
for IgG replacement but had not yet started therapy were in-
cluded. Patients with a life expectancy of <1 year, dementia or
mental incapacity, or with comorbidities or other conditions
that would interfere with the data interpretation were exclud-
ed. Patients who were currently receiving IgG or had received
IgG in the recent past were also not eligible for the study.
Patients or their caregivers provided written informed consent
and were enrolled in the study from September 2010 to
December 2012. IgG treatment regimen and dosing intervals
were per the discretion of the treating physician.
Data Collection
Patients were assessed at two time points. Baseline assessment
occurred after confirmation of the diagnosis and during the
2 weeks before first IgG infusion or on the first day of treat-
ment. The follow-up assessment took place 12 months after
initiation of IgG treatment (±1 month), with the last patient
follow-up completed in December 2013. At each assessment,
serious infections, or other acute or chronic infections (eg,
acute chronic sinusitis; bronchitis; bacterial pneumonia; bac-
teremia or sepsis; osteomyelitis or septic arthritis; visceral ab-
scess; bacterial meningitis; and ear infection) were captured,
and patients completed self-administered questionnaires to
evaluate quality of life and health resource utilization.
Pediatric patients aged 8–17 years completed the question-
naire with the help of their caregiver (parent/guardian).
Caregivers completed the questionnaire on behalf of patients
aged <8 years. Collected data were entered into an electronic
database for analysis.
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Adult patients and caregivers of pediatric patients complet-
ed the 36-item Short FormHealth Survey, version 2 (SF-36v2)
[33, 34]. The SF-36v2 survey is a validated and frequently
used [35, 36] measure of HRQOL that evaluates eight
domains related to functional health status and emotion-
al well-being. These eight domains can be categorized
into higher-order clusters of physical health (physical
function, role—physical, bodily pain, general health)
and mental health (vitality, social function, role – emo-
tional, and mental health).
Pediatric patients (age <18 years) were evaluated with the
Pediatric Quality of Life Inventory (PedsQL) measurement
instrument [37]. The PedsQL survey is a validated, reliable
[38] measure of HRQOL specifically for the pediatric popu-
lation that evaluates physical, emotional, social, and school-
related parameters.
A health resource utilization questionnaire was also admin-
istered at baseline to collect information on hospitalizations,
emergency room visits, antibiotic use and days missed from
work or school in the 6 months prior to enrollment. Patients
were also given a diary for recording healthcare utilization
during the 12-month study period.
Statistical Analysis
The primary endpoint for the analysis was the baseline and the
12-month follow up quality-of-life (QOL) score. Secondary
endpoints included occurrence of hospitalization, emergency
room visits, office visits for PIDD-related events, and use of
medications, such as antibiotics for these time points.
Descriptive statistical analyses were carried out for all primary
and secondary endpoint parameters.
Using the normative data available for the SF-36v2,
comparative samples were age- and sex-matched using
separate least squares multiple regression models for
each QOL scale and summary measure. While the SF-
36v2 normative database is based on US respondents
only, research has shown that the US-based norms are
valid and appropriate for interpreting scores of respon-
dents from other countries [39].
The SF-36v2 normative database allowed for comparisons
to a general US population as well as subgroups within that
population with the following chronic conditions: rheumatoid
arthritis, chronic obstructive pulmonary disease (COPD), con-
gestive heart failure (CHF), cancer, and chronic back pain. A
univariate analysis of variance model was used to test differ-
ences between the SF-36v2 scores for patients with PIDD and
patients from the comparative groups. The PedsQL has pub-
lished normative data from healthy and chronic conditions,
including asthma, cancer, diabetes, and rheumatology
for comparison purposes [37]. Because the normative
data for the PedsQL are in published form only, 95 %
confidence intervals were used to assess differences
between scores for patients with PIDD and patients
from the comparative groups.
A power calculation to determine the appropriate sample
size for this study was not conducted due to the lack of his-
torical results to estimate the potential effect size for the
HRQOL endpoints and due to the exploratory nature of the
study without a formal hypothesis formulated or tested. The
study aimed to include 30 or more patients with PIDD; due to
the rarity of PIDD and the challenge of finding newly diag-
nosed patients naïve to IG therapy, such a number was con-
sidered to be reasonably attainable, while adding valuable
information to conduct an exploratory analysis of the stated
endpoints.
Determination of Clinically Relevant Differences
Changes in SF-36 scores prior to and following IgG treatment
initiation were compared with known minimally important
differences (MID) for each category [40]. Changes that met




A total of 31 patients (11 each from the United States and
Brazil, and 9 from the United Kingdom) were enrolled in the
study. The enrolled population included 21 (66.7 %) adult
patients and 10 (33.3 %) pediatric patients. Six patients
discontinued early due to treatment noncompliance (1 adult),
home relocation (1 pediatric), and unknown reasons (3
adults and 1 pediatric). Baseline assessments were com-
pleted by 17 adult patients, 8 pediatric patients, and 8
caregivers, while 12-month assessments were completed
by 14 adults, 6 pediatric patients, and 8 caregivers.
Missing data from 2 of the pediatric patients precluded
their inclusion in the follow-up analyses.
Baseline characteristics for the 25 patients and 8 caregivers
included in the analysis are summarized in Table 1. The mean
age was 47.7 years (standard deviation [SD]=12.9) for adult
patients and 5.1 years (SD=4.8) for pediatric patients. CVID
was the most frequently occurring diagnosis amongst the
adults (14/21, 66.6 %), while hypogammaglobulinemia was
the most common diagnosis among the pediatric patients
(4/8, 50 %).
QOL Assessment in Adult Patients
Seventeen of the 21 adults enrolled completed SF-36v2
assessments prior to IVIG treatment initiation (baseline);
the 3 adult patients who did not complete the
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assessments after 12 months of treatment were excluded
from the baseline SF-36v2 analyses. Prior to treatment
initiation, adult patients who were diagnosed with PIDD
had diminished HRQOL compared with the general US
population and patients with other chronic conditions
(Fig. 1a and b). The mean Physical Component
Summary (PCS) score for adult patients (N= 17) with
PIDD was 37.4, which was significantly lower than in
the general US population (50.5; N = 4,024; p < 0.01),
and in patients with various types of cancer, excluding
skin cancer (44.4, N = 311; p < 0.05) or chronic back
pain (44.1, N= 893; p< 0.05) (see Fig. 1a). In the phys-
ical health domains of the SF-36v2 (physical function-
ing, role—physical, bodily pain, general health), adult
patients with PIDD prior to treatment had significantly
lower scores for all 4 domains compared with the gen-
eral US population (p< 0.05), and compared with pa-
tients suffering from other chronic conditions for role-
physical (p< 0.05 for rheumatoid arthritis, cancer, chron-
ic back pain) and general heal th (p < 0.05 for










Mean (SD) 47.1 (13.2) 5.5 (5.4) 32.8 (8.6)
Min-max 24–67 0–17 23–47
Sex, n (%)
Male 6 (35.3) 5 (62.5) 0 (0)
Female 11 (64.7) 3 (37.5) 8 (100)
Diagnosis, n (%)
CVID 11 (64.7) 2 (25) N/A
Othera 6 (35.3) 6 (75) N/A
Agammaglobulinemia 1 (5.9) 0 (0) N/A
Hypogammaglobulinemia 2 (11.7) 4 (50) N/A
Specific antibody deficiency 3 (17.6) 2 (25) N/A
Working status, n (%)
Work full-time (≥35 h/week) 9 (52.9) N/A 2 (25.0)
Work part-time (<35 h/week) 2 (11.8) N/A 2 (12.5)
Stay-at-home parent 0 (0) N/A 1 (12.5)
Disabled 1 (5.9) N/A 1 (12.5)
Unemployed 0 (0) N/A 3 (37.5)
Retired 4 (23.5) N/A 0 (0)
Other 1 (5.9) N/A 0 (0)
Marital status, n (%)
Single 4 (23.5) N/A 1 (12.5)
Married 103 (58.8) N/A 4 (50.0)
Divorced 1 (5.9) N/A 3 (37.5)
Other 2 (11.8) N/A 0 (0)
Race
White or Caucasion 17 (100.0) 7 (87.5) N/A
African-American 0 (0) 1 (12.5) N/A
Location of infusions
Home 2 (11.8) 0 (0) N/A
Infusion center 15 (88.2) 8 (100) N/A
a Patients in this category were all deemed suitable candidates for the current study and for IgG replacement treatment
CVID common variable immunodeficiency (CVID), IgG immunoglobulin G), max maximum), min minimum), N/A not applicable), SD standard
deviation
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rheumatoid arthritis, COPD, and CHF; p< 0.01 for can-
cer and chronic back pain).
Similarly, the mean Mental Component Summary
(MCS) score was significantly lower for adult patients
with PIDD (41.6; n= 17) compared with the general US
population (49.2, N = 4,024; p < 0.05) (see Fig. 1b).
Furthermore, the MCS for adult patients with PIDD
was lower, but not statistically significant, than MCS
values reported by patients with other chronic condi-
tions (including rheumatoid arthritis, COPD, CHF, can-
cer, and chronic back pain). For the mental health do-
mains of the SF-36v2, adult patients with PIDD experi-
enced significantly diminished (p < 0.05) vitality (38.2
vs. 49.4), social functioning (33.6 vs. 49.8), and
role—emotional (41.0 vs. 49.7), but not mental health,
compared with the general US population. Adult pa-
tients with PIDD also reported significantly lower scores
for social functioning (p< 0.05 for rheumatoid arthritis,
COPD, CHF, cancer, and chronic back pain) and vitality
(p< 0.05 for CHF and cancer) relative to age-matched
patients with chronic diseases.
Of the 17 adult patients assessed for QOL at base-
line, 14 were assessed twelve months after IgG treat-
ment initiation. Comparing baseline and follow up data
for these 14 patients, increases in both PCS (from 36.9
to 43.2; Fig. 2a) and MCS (from 46.0 to 49.0; Fig. 2b)
were observed. While these differences were not signif-
icant, the change in PCS (6.3) after IgG treatment
exceeded the MID of 3.8 and may be clinically rele-
vant. Furthermore, significant and clinically relevant in-
creases were observed in a number of physical and
mental individual domain scores, including role-
physical (p= 0.01; observed change = 10.6, MID = 4.0),
general health (p < 0.01; observed change = 9.1,
MID = 7.0), and social functioning (p = 0.02; observed
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Fig. 1 SF-36 physical (a) and
mental (b) summary and domain
scoresa for adult patients with
PIDD compared with patients
with other chronic conditions and
US general population. aPhysical
functioning, role physical, bodily
pain, and general health are
domains of the physical
component scores; vitality, social
functioning, role emotional, and
mental health are domains of the
mental component score.
*p< 0.05 compared with PIDD
sample. **p< 0.01 compared
with PIDD sample. CHF,
congestive heart failure; COPD,
chronic obstructive pulmonary




36, short form health survey; US,
United States
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QOL Assessment in Pediatric Patients
Eight of the 10 enrolled pediatric patients completed PedsQL
assessments at baseline; the 2 patients who did not complete
both assessments were excluded from the PedsQL analyses.
According to baseline PedsQL scores, pediatric patients diag-
nosed with PIDD experienced diminished HRQOL compared
with the healthy pediatric population (Fig. 3). Those with
PIDD (N=8) had significantly lower (p=0.05) PedsQL total
scores (63.1 [95 % confidence interval; CI: 48.4–77.9] vs.
82.7 [95 % CI: 82.4–83.0]), physical summary scores (64.5
[95 % CI: 46.7–82.2] vs. 84.5 [95 % CI: 84.1–84.9]), and
psychosocial summary scores (62.5 [95 % CI: 48.0–77.0]
vs. 81.7 [95 % CI: 81.3–82.0]) compared with the general
US population (N=9,430). The total scores, physical summa-
ry scores, and psychosocial summary scores were also lower
for pediatric patients with PIDD relative to those with asthma
(N=157), diabetes (N=307), cancer (N=561), and rheuma-
tology conditions (N=357), with the exception of physical
summary score comparability of PIDD with rheumatology
conditions.
Of the 8 pediatric patients with PIDD assessed at baseline,
6 completed assessments 12 months following IgG treatment
initiation. No significant or clinically meaningful differences
in total, physical summary, or psychosocial summary scores
were reported (Fig. 4).
Figure 5 illustrates the change in PedsQL scores from base-
line to 12 months for each individual pediatric patient.
Examination of these individual changes shows a wide varia-
tion in the PedsQL scores between patients.
Health Resource Utilization in Adult and Pediatric
Patients
Health resource utilization among patients with PIDD prior to
and after IgG treatment initiation is summarized in Table 2.
Adult and pediatric patients as a group reported a significantly











































Vitality Social functioning Role emotional Mental health












































Role physical Bodily pain General health
ns ns p=0.01 ns p=0.001
Fig. 2 SF-36 physical (a) and
mental (b) component and
domain scoresa of adult patients
with PIDD at baseline and at
12 months following IgG
treatment initiation. aPhysical
functioning, role physical, bodily
pain, and general health are
domains of the physical
component scores; vitality, social
functioning, role emotional, and
mental health are domains of the
mental component score.
————— SF-36 US general
population norms, Δ, difference.
MID, minimally important
difference; ns, not significant;
PIDD, primary
immunodeficiency disease; SF-
36, 36-item Short Form Health
Survey; US, United States
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0.21; p < 0.01), serious infections (n = 18; 10.9 vs 3.3;
p< 0.01), and antibiotic prescriptions (n= 22; 7.1 vs 3.0;
p<0.01) after initiation of IgG treatment compared with base-
line. An adult-only sub analysis further showed a significant
decrease in mean emergency room visits associated with IgG
treatment (n=17; 1.8 at baseline vs 0.4 post-treatment initia-
tion, p=0.04). Additionally, pediatric patients had significant-
ly fewer mean number of unscheduled office visits (n=7; 20.0
vs 8.3, p= 0.01) after treatment initiation compared with
baseline.
Patient Productivity
Adult and pediatric patients with PIDD experienced a reduc-
tion in productivity in the 6 months preceding treatment initi-
ation. After initiation of IgG treatment, adult patients (n=12)
reported a non-significant increase in days missed from
work/school (mean 25.5 days prior to IgG treatment and
37.4 days after 12 months of IgG treatment), while pediatric
patients (n= 4) reported 63.5 and 46.0 days missed from
school, prior to and after IgG treatment initiation, respectively
(see Table 2).
QOL Assessment in Caregivers of Pediatric Patients
Eight caregivers completed SF-36v2 assessments at baseline
and 12 months following IgG treatment initiation; the 2 care-
givers who did not complete both assessments were excluded
from the SF-36 analyses. While caregivers did not report a
significant difference in PCS (Fig. 6a) or MCS (Fig. 6b) fol-
lowing IgG treatment, MCS was numerically higher (38.0vs
30.9) and clinically relevant (observed change = 7.1;
MID=4.6) after 12 months of treatment compared with base-
line. Furthermore, compared with baseline, caregivers also








































US healthy population (N=9,430)
Fig. 3 PedsQL total, physical,
and psychosocial summary scores
of pediatric patients with PIDD
compared with pediatric patients
with other chronic conditions and
the US healthy population. The
black bars represent the 95 %
confidence intervals. PedsQL,
pediatric quality of life; PIDD,
primary immunodeficiency
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Δ0.3
Fig. 4 PedsQL scores among
pediatric patients with PIDD at
baseline and at 12 months
following IgG treatment
initiation. aMIDs were not




ns, not significant; PedsQL,
Pediatric Quality of Life; PIDD,
primary immunodeficiency
diseases; US, United States
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reported a significantly higher (47.0 vs. 38.8, p<0.01) and
clinically relevant (observed change=8.2,MID=6.7) domain
score for vitality after treatment (see Fig. 6b). Clinically rele-
vant (but not statistically significant) increases in social func-
tioning (observed change=6.9,MID=6.2) and mental health
(observed change = 7.8, MID = 6.7) were also reported
(see Fig. 6b).
Discussion
Recent data suggest that although the prevalence of PIDD is
higher than once thought [41], patients continue to experience
significant delays in diagnosis [17, 25, 26]. The present study
sought to gain insight into the burden of disease among newly
diagnosed patients with antibody deficiencies and to explore
HRQOL and HRU following the initiation of IgG treatment.
The SF-36 and PedsQL surveys used to assess HRQOL in
adult and pediatric patients, respectively, in the current survey
have previously been used in other studies of patients with
PIDD [18, 21, 22, 28–30, 34]. The results presented herein
suggest that adult and pediatric patients with PIDD have di-
minished HRQOL and productivity prior to the initiation of
IgG treatment, and that following 12months of IgG, adult (but
not pediatric) patients experienced improved HRQOL, as
reflected by significant and clinically relevant increases in 2
physical health and 1 mental health domain scores in the SF-
36 survey. Furthermore, the data also suggest improved
HRQOL for pediatric patients’ caregivers, who reported a
significant increase in their own vitality following 12 months
of IgG treatment of their children. Notably, clinically mean-
ingful increases in social functioning and mental health do-
main scores were also observed for caregivers. In addition,
significant decreases were reported in a number of HRU cat-
egories for both adult and pediatric patients. Compared with
baseline, however, the number of missed days at work (adults)
or school (pediatric patients) was not significantly different
following IgG treatment.
The wide variation in the PedsQL scores observed between
individual pediatric patients (see Fig. 5) suggests that while
some pediatric patients reported an improvement after
12 months of treatment, others reported no change or worsen-
ing of their HRQOL. However, these data are difficult to in-
terpret due to the low number of pediatric patients in our study
population. Although the wide variation may reflect a true
















































Fig. 5 PedsQL scores among
individual pediatric patients with
PIDD at baseline and at
12 months following IgG
treatment initiation. IgG,
immunoglobulin G; PedsQL,
Pediatric Quality of Life; PIDD,
primary immunodeficiency
diseases
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Table 2 Mean health resource utilization per patient before and 12 months after IgG treatment initiation






p-value n Baseline (12-Months
Pre-treatment),a
Mean (SD)
12 Months, Mean (SD) p-value
Regularly scheduled office visits 16 7.1 (7.8) 8.9 (8.7) NS 7 10.6 (5.3) 11.3 (5.7) NS
Unscheduled office visits 17 11.6 (15.6) 3.8 (5.4) NS 7 20.0 (9.2) 8.3 (6.8) 0.01
Emergency room visits 17 1.8 (2.4) 0.4 (0.7) <0.05 7 6.3 (8.3) 1.9 (3.3) NS
Hospital admissions 17 1.4 (2.4) 0.2 (0.4) 0.05 8 2.8 (2.1) 0.4 (0.5) 0.01
Length of stayb – – – 3 46.0 (46.1) 7.7 (8.1) NS
Number of serious infectionsc 12 8.0 (7.2) 2.5 (1.6) <0.05 6 16.7 (9.0) 5.0 (2.1) <0.05
Days missed from work or schoold 12 25.5 (36.9) 37.4 (103.4) NS 4 63.5 (77.8) 46.0 (36.5) NS
Number of antibiotic prescriptions 16 5.5 (4.0) 2.5 (2.3) <0.01 6 11.3 (9.0) 4.2 (2.6) NS
a Pre-enrollment data was annualized
bOnly 1 adult patient had length-of-stay data
c Serious infections defined as: acute or chronic sinusitis, bronchitis, pneumonia, ear infection, or other acute or chronic infection
d Four adult patients who were retired were excluded from this analysis






















































































Role physical Bodily pain General health
ns p=0.008 ns ns ns
ns ns ns ns ns
Fig. 6 SF-36 physical (a) and
mental (b) component and
domain scoresa for caregivers of
pediatric patients with PIDD at
baseline and at 12 months
following IgG treatment
initiation. aPhysical functioning,
role physical, bodily pain, and
general health are domains of the
physical component scores;
vitality, social functioning, role
emotional, and mental health are
domains of the mental component
score.————— SF-36 US
general population norms. Δ,
difference. MID, minimally
important difference; ns, not
significant; PIDD, primary
immunodeficiency disease; SF-
36, 36-item Short Form Health
Survey; US, United States
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may also reflect an aberration within our small study sample;
specific trends may be elucidated with a larger sample size.
While several studies have investigated HRQOL in adult
and pediatric patients with PIDD following IgG replacement
[18, 21–23, 28–32], none have compared HRQOL in the same
cohort prior to and after treatment initiation. In general, data
from previous studies have shown a lower HRQOL in patients
with PIDD compared with the general population, including
adult patients with CVID [18] and select IgA deficiency [28].
Similar results were reported from studies focusing on pediat-
ric patients in which significantly lower PedsQL scores were
observed in those with PIDD compared with healthy individ-
uals [29, 31, 32]. However, in a survey of 25 adult males with
XLA, numerically, but not significantly, lower QOL scores,
compared with the general US population, were reported [23].
In the current study, QOL and HRU were assessed within
the same patient cohort both prior to PIDD diagnosis and
following 12 months of IgG replacement therapy. At baseline,
adults with PIDD had significantly lower PCS and MCS (SF-
36) compared with the general US population and significant-
ly lower PCS compared with patients with chronic back pain
and cancer. The mental burden, on the other hand, was similar
between adults with PIDD and patients with other chronic
conditions. Similarly, pediatric patients diagnosed with
PIDD experienced a substantial HRQOL burden of dis-
ease, as was evident from the lower PedsQL scores than
the general US population. When compared with pedi-
atric patients with other chronic diseases, including can-
cer, asthma, and rheumatologic diseases, scores were
either similar or lower.
Patients were followed after 12 months of IgG treatment.
After treatment, patients documented lower HRUwith regards
to hospital admissions, serious infections, and antibiotic pre-
scriptions. Adult patients reported a significant increase in the
role-physical and general health domain scores of PCS and in
the vitality domain of the MCS. These results are consistent
with other studies that have noted an inverse relationship be-
tween persistence of symptoms (ie, serious infections, chronic
diarrhea) and SF-36 scores [18, 30]. While previous studies
have primarily indicated a QOL deficit in patients with PIDD
who are already receiving treatment compared with healthy
populations or patients with other chronic diseases, the current
study indicates that adult patients do experience an improve-
ment in QOL following IgG treatment initiation. However,
this study did not collect interim assessment data (ie, within
the 12 months of treatment); therefore, an opportunity was
missed to compare differences in improvement during, eg,
the first 6 months of IgG treatment to the last 6 months of
IgG treatment.
In addition to evaluating patients with PIDD, the current
study also surveyed caregivers (mothers) of pediatric patients
with PIDD. Notably, caregivers reported a significant increase
in the vitality domain as well as clinically relevant differences
in the social functioning and mental health domains of MCS
after their children initiated IgG replacement, suggesting that
the QOL benefit may extend beyond the patients themselves.
However, both pediatric and caregiver results should be
interpreted with caution due to the particularly low number
of subjects in these analyses (as further illustrated by the var-
iation in individual pediatric PedsQL data in Fig. 5).
The present study focused on patients with antibody defi-
ciencies, and the small sample size (particularly the low num-
ber of pediatric patients and their caregivers) presented here
may not accurately reflect the general population of patients
with PIDD. Further, since a power calculation was not con-
ducted, this study may have been underpowered to adequately
detect the true effect of treatment on patient HRQOL. Because
of the small number of patients in the current study, additional
analyses are limited. For example, it is not statistically plausi-
ble to compare the socioeconomic status and geographical
areas of the patients. It is also important to consider that self-
reported survey results are always subject to potential bias
because patients and caregivers may not accurately remember
or report details of their condition. In the current analysis, we
compared scores from patients with PIDD (prior to and after
treatment with IgG) to the SF-36v2 normative database with-
out information regarding the treatment status of patients with
chronic conditions included in the database. If some or all of
the patients with chronic conditions had received treatments, it
might impact their HRQOL and subsequently influence our
comparison. Furthermore, while prior research has shown that
using the US-based SF-36v2 norms for interpreting scores
across adult respondents from different countries is appropri-
ate (between-score correlations of 0.98–1.00 for physical and
mental components in all 9 European countries evaluated)
[39], the comparability with the patients from our sample from
other countries may be limited because the SF-36v2 norma-
tive database contains only US respondents. Similarly, the
PedsQL survey has been translated (with cultural adaptations)
and validated for use in numerous countries (PedsQL: http://
pedsql.org/pedsql2.html). Although the PedsQL has been
validated among different ethnic and racial backgrounds
within a US population [38], to our knowledge no cross-
country validation studies of the PedsQL survey have been
published.
Conclusions
In the current analysis, prior to IgG replacement, adult and
pediatric patients with PIDD suffered from diminished
HRQOL compared with the general US population and pa-
tients with other chronic diseases. In addition, patients expe-
rienced diminished productivity due to the number of work
and/or school days that were missed because of their condi-
tion. Twelve months after IgG treatment initiation, adult
J Clin Immunol (2016) 36:450–461 459
patients and caregivers of pediatric patients reported an im-
provement in QOL. Additionally, HRU decreased for the
overall population, including pediatric patients.
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